Background::Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods::Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients ( n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group ( n = 56) and a twice or three times per week intravenous epoetin alfa group ( n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS? software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators. Results::The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion::Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.

anemia;chronic renal failure;darbepoetin alfa;hemodialysis;recombinant human erythropoietin

Chen Nan;Xing Changying;Niu Jianying;Liu Bicheng;Fu Junzhou;Zhao Jiuyang;Ni Zhaohui;Wang Mei;Liu Wenhu;Zhao Jinghong;Zhong Ling;Wu Xiongfei;Li Wenge;Chen Yuqing;Shi Wei;Chen Jianghua;Yin Aiping;Fu Ping;Wang Rong;Jiang Gengru;Hou Fanfan;Ding Guohua;Chen Jing;Xu Gang;Kondo Yuichiro;Su Yuliang;Mei Changlin

Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd, Tokyo 520-5292, Japan;D&R office, Kyowa Kirin China Pharmaceutical Co., Ltd, Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China

慢性疾病与转化医学（英文）

[1]Chen Nan;Xing Changying;Niu Jianying;Liu Bicheng;Fu Junzhou;Zhao Jiuyang;Ni Zhaohui;Wang Mei;Liu Wenhu;Zhao Jinghong;Zhong Ling;Wu Xiongfei;Li Wenge;Chen Yuqing;Shi Wei;Chen Jianghua;Yin Aiping;Fu Ping;Wang Rong;Jiang Gengru;Hou Fanfan;Ding Guohua;Chen Jing;Xu Gang;Kondo Yuichiro;Su Yuliang;Mei Changlin-.Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail)[J].慢性疾病与转化医学（英文）,2022(01):59-70

Darbepoetin,epoetin,darbepoetin

alfa,versus,treating,anemia,Chinese,hemodialysis,patients,chronic,kidney,failure,randomized,open,label,parallel,inferiority,Phase,III,trail,Background,Erythropoietin,glycoprotein,that,mainly,regulates,erythropoiesis,In,renal,can,stimulate,correct,hemoglobin,levels,This,study,was,designed,demonstrate,efficacy,safety,injections,being,not,Recombinant,Human,rHuEPO,when,maintaining,Hb,within,target,range,dL,treatment,Methods,Ninety,five,were,enrolled,this,from,April,sites,aged,years,into,once,twice,three,times,weeks,who,had,between,due,disease,CKD,undergoing,hemofiltration,ESA,naive,stimulating,agent,primary,mean,margin,secondary,profiles,increase,achievement,cumulative,trends,maintenance,Adverse,events,AEs,observed,compared,analyzed,two,groups,Additionally,frequencies,dose,adjustments,during,period,SAS,software,version,used,perform,statistical,analyses,Descriptive,statistics,demographic,variable,including,indicators,Results,respectively,lower,limits,confidence,intervals,proven,started,first,four,similar,obvious,differences,rates,well,changed,over,incidence,All,adverse,those,commonly,associated,Conclusion,intravenously,effectively,which,makes,shows,comparable,recombinant,human,erythropoietin

0.354524